Coherus Oncology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Coherus Oncology Inc.
- Former names
- Coherus BioSciences, Inc. BioGenerics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CHRS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001512762
- EIN
- 27-3615821
Board of directors
-
Ali J. Satvat · DirectorSince 2025
-
Charles W. Newton · DirectorSince 2023
-
Dennis M. Lanfear · Director · President & CEOSince 2023
-
Georgia Erbez · DirectorSince 2024
-
Jill O'Donnell-Tormey · DirectorSince 2023
-
Kimberly Jo Tzoumakas · DirectorSince 2023
-
Lee Nisley Newcomer · DirectorSince 2023
-
Mark Stolper · DirectorSince 2023
-
Mats Wahlstrom · DirectorSince 2023
-
Michael Lee Ryan · DirectorSince 2023
-
Rita A. Karachun · DirectorSince 2024
Chief executives
Dennis M. Lanfear
· President & CEO
Dates unknown
Director election results
Annual meeting of June 11, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.3%
-
84.1%
-
84.2%
Board connections
6 of this board's directors also sit on 6 other boards.
- via Kimberly Jo Tzoumakas and Mark Stolper
- via Ali J. Satvat
- via Charles W. Newton
- via Lee Nisley Newcomer
- via Charles W. Newton
- via Mats Wahlstrom
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 5, 2026 | Ali J. Satvat Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Rita A. Karachun Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Lee Nisley Newcomer Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Michael Lee Ryan Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Jill O'Donnell-Tormey Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Mats Wahlstrom Director | Grant or award | +30,000 | — | — |
| Jun 5, 2026 | Charles W. Newton Director | Grant or award | +30,000 | — | — |
| Jan 23, 2026 | Dennis M. Lanfear Director, Officer (President & CEO) | Grant or award | +375,000 | — | — |
| Jan 22, 2026 | McMichael Bryan J Officer (Chief Financial Officer) | Grant or award | +112,500 | — | — |
| Jan 20, 2026 | McMichael Bryan J Officer (Chief Financial Officer) | Shares withheld for tax | −1,715 | $1.55 | $2,658 |
| Jan 20, 2026 | Dennis M. Lanfear Director, Officer (President & CEO) | Shares withheld for tax | −11,839 | $1.55 | $18,350 |
| May 23, 2025 | Mats Wahlstrom Director | Open-market sale | −99,988 | $0.74 | $73,991 |
| Jan 20, 2025 | McMichael Bryan J Officer (Chief Financial Officer) | Shares withheld for tax | −1,711 | $1.39 | $2,378 |
| Jan 20, 2025 | Reider Paul Officer (Chief Commercial Officer) | Shares withheld for tax | −4,858 | $1.39 | $6,753 |
| Jan 20, 2025 | Dennis M. Lanfear Director, Officer (President & CEO) | Shares withheld for tax | −11,810 | $1.39 | $16,416 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.